相似文献
1
Hepatitis B virus reactivation with rituximab-containing regimen.
World J Hepatol. 2013 Nov 27;5(11):612-20. doi: 10.4254/wjh.v5.i11.612.
2
Prevention of hepatitis B virus reactivation under rituximab therapy.
Immunotherapy. 2009 Nov;1(6):1053-61. doi: 10.2217/imt.09.59.
3
Rituximab administration and reactivation of HBV.
Hepat Res Treat. 2010;2010:182067. doi: 10.1155/2010/182067. Epub 2010 Dec 1.
4
Reactivation of hepatitis B virus with rituximab.
Expert Opin Drug Saf. 2005 May;4(3):599-608. doi: 10.1517/14740338.4.3.599.
5
Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.
Leuk Lymphoma. 2004 Mar;45(3):627-9. doi: 10.1080/1042819031000151923.
6
Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy.
Support Care Cancer. 2013 May;21(5):1265-71. doi: 10.1007/s00520-012-1656-8. Epub 2012 Nov 15.
7
Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Ann Hematol. 2004 Jan;83(1):58-60. doi: 10.1007/s00277-003-0748-4. Epub 2003 Sep 26.
8
Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
Yonsei Med J. 2007 Feb 28;48(1):78-89. doi: 10.3349/ymj.2007.48.1.78.
9
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
JAMA. 2014 Dec 17;312(23):2521-30. doi: 10.1001/jama.2014.15704.
10
Hepatitis B virus reactivation with a rituximab-containing regimen.
World J Hepatol. 2015 Sep 28;7(21):2344-51. doi: 10.4254/wjh.v7.i21.2344.
引用本文的文献
1
Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action.
J Clin Med. 2023 Dec 19;13(1):15. doi: 10.3390/jcm13010015.
2
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies.
Emerg Microbes Infect. 2023 Dec;12(1):2219347. doi: 10.1080/22221751.2023.2219347.
3
Animal models applied to acute-on-chronic liver failure: Are new models required to understand the human condition?
World J Clin Cases. 2022 Mar 26;10(9):2687-2699. doi: 10.12998/wjcc.v10.i9.2687.
4
Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies.
Front Immunol. 2021 Aug 30;12:731643. doi: 10.3389/fimmu.2021.731643. eCollection 2021.
5
Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.
Front Immunol. 2021 Jul 15;12:638678. doi: 10.3389/fimmu.2021.638678. eCollection 2021.
6
Quality Initiative in Clinical Practice: A Single-Institution Appraisal of Quality Metrics in the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma.
Mayo Clin Proc Innov Qual Outcomes. 2019 Oct 22;3(4):485-494. doi: 10.1016/j.mayocpiqo.2019.08.004. eCollection 2019 Dec.
7
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.
Hepatol Int. 2019 Jul;13(4):353-390. doi: 10.1007/s12072-019-09946-3. Epub 2019 Jun 6.
8
Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan.
BMC Gastroenterol. 2018 Jan 8;18(1):6. doi: 10.1186/s12876-017-0735-1.
9
Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B.
Haematologica. 2016 Jul;101(7):e303-5. doi: 10.3324/haematol.2016.144840. Epub 2016 Apr 21.
10
Hepatitis B virus reactivation with a rituximab-containing regimen.
World J Hepatol. 2015 Sep 28;7(21):2344-51. doi: 10.4254/wjh.v7.i21.2344.
本文引用的文献
1
Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
J Clin Oncol. 2013 Aug 1;31(22):2765-72. doi: 10.1200/JCO.2012.48.5938. Epub 2013 Jun 17.
2
Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011.
Dan Med J. 2012 Jun;59(6):C4465.
3
HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
Int J Hematol. 2012 May;95(5):588-91. doi: 10.1007/s12185-012-1050-9. Epub 2012 Mar 16.
4
Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
Ann Hematol. 2012 Jul;91(7):1007-12. doi: 10.1007/s00277-012-1405-6. Epub 2012 Jan 25.
5
Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy.
Liver Int. 2011 Mar;31(3):330-9. doi: 10.1111/j.1478-3231.2010.02332.x. Epub 2010 Aug 25.
6
How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation.
Blood. 2009 Apr 2;113(14):3147-53. doi: 10.1182/blood-2008-10-163493. Epub 2009 Jan 14.
7
Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution.
Clin Transplant. 2009 Jun-Jul;23(3):431-4. doi: 10.1111/j.1399-0012.2008.00936.x. Epub 2008 Dec 10.
8
Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
J Clin Oncol. 2009 Feb 1;27(4):605-11. doi: 10.1200/JCO.2008.18.0182. Epub 2008 Dec 15.
9
EASL Clinical Practice Guidelines: management of chronic hepatitis B.
J Hepatol. 2009 Feb;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001. Epub 2008 Oct 29.
10
Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab.
J Med Virol. 2008 Dec;80(12):2069-78. doi: 10.1002/jmv.21311.
Zotero 插件